12月7日周末公告汇总 | 光启技术签订7亿元航空超材料产品合同；多家公司创新药进入医保目录

Group 1: Stock Resumption and Suspension - Jiahua Technology plans to acquire 90% of Shudun Technology, focusing on domestic cryptography technology research and information security solutions, leading to stock resumption [1] - Annie Co. will have Shengshi Tianan as its controlling shareholder, resulting in stock resumption [1] - ST Tianrui has terminated plans for a change in company control, leading to stock resumption [1] - Gu'ao Technology's actual controller is planning a change in control, resulting in stock suspension [1] Group 2: Share Buybacks and Increases - Meilixin's controlling shareholder intends to increase company shares by 50 million to 100 million yuan [2] Group 3: Investment Cooperation and Operational Status - Shangwa New Materials plans to purchase software code usage rights for 26 million yuan [3] - Hengdian East Magnet's chip inductors have entered major enterprises, achieving rapid shipment growth [3] - Roman Co.'s subsidiary signed a contract worth approximately 448 million yuan for computing power equipment sales and services [3] - Guangqi Technology's subsidiary signed a contract worth 696 million yuan to deliver metamaterial aerospace structural products [3] - Yanshan Technology's subsidiary Nullmax (Cayman) plans to introduce a leading domestic automotive-grade chip company as a strategic investor [3] - Aerospace Electric's subsidiary Suzhou Huazhan Investment is investing 57.25 million yuan to build production capacity for high-speed modules and liquid cooling interconnect products [3] - East China Pharmaceutical's wholly-owned subsidiary's products have been included in the national medical insurance and commercial insurance innovative drug catalog [3] - Fosun Pharma has multiple drugs newly included in the national medical insurance and commercial insurance innovative drug catalog [3] - Ailis's innovative drugs have been included in the new version of the national medical insurance catalog [3] - Aidi Pharmaceutical's two anti-HIV innovative drugs have renewed their entry into the national medical insurance catalog [3] - Dongcheng Pharmaceutical's 177Lu-LNC1009 injection clinical trial has been approved, with no similar products currently on the market [4] - Weike Technology primarily provides products such as robot motor insulation ends and has achieved mass sales, collaborating with global companies like DANFOSS [4] - Double Star New Materials has reached a consensus on production reduction in the BOPET industry under the "Industry Self-Discipline Initiative" [4] - Wanliyang has invested in production lines for precision transmission products for robot joints, expected to reach mass production by May 2026 [4]